- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Radiofrequency device for skin treatment wins FDA approval
Syneron Medical Ltd., based here, has received U.S. Food and Drug Administration (FDA) approval for its Matrix RF applicator for use in dermatological procedures requiring skin ablation and resurfacing, CNNMoney.com reports.
Yokneam, Israel — Syneron Medical Ltd., based here, has received U.S. Food and Drug Administration (FDA) approval for its Matrix RF applicator for use in dermatological procedures requiring skin ablation and resurfacing, CNNMoney.com reports.
Syneron had received CE mark clearance in Europe shortly before the FDA announced its approval of the Matrix RF.
The Matrix RF uses radiofrequency technology to provide ablation and resurfacing through fractional tissue heating at three relative ratios. The applicator can be adjusted to customize ablation depth and degree of skin resurfacing based on individual patient needs.
According to CNNMoney.com, the Matrix RF is the first non-laser or non-light-based device capable of tunable ablation and resurfacing.
The Matrix RF will be sold as an add-on to the company’s eLight, eLaser and eMax platforms. It is the second product in Syneron’s series of fractional skin-treatment devices, which currently includes the Matrix IR for nonablative fractional treatments.
